Larson and Gill [226] demonstrated that FGF21 signalling was dysregulated in both AD and cardiometabolic disorders such as T2D, suggesting that FGF21 could be a possible link between AD and T2D. This evidence concerns the gene FGF21 and Alzheimer disease.